title: Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials.
abstract: Dyslipidemia is one of the most common adverse effects in schizophrenia patients treated with antipsychotics. However, there are no established effective treatments. In this study, data were pooled from two randomized, placebo-controlled trials, which were originally designed to examine the efficacy of metformin in treating antipsychotic-induced weight gain and other metabolic abnormalities. In total, 201 schizophrenia patients with dyslipidemia after being treated with an antipsychotic were assigned to take 1000 mg day-1metformin (n=103) or placebo (n=98) for 24 weeks, with evaluation at baseline, week 12 and week 24. The primary outcome was the low-density lipoprotein cholesterol (LDL-C) levels. After metformin treatment, the mean difference in the LDL-C value between metformin treatment and placebo was from 0.16 mmol l-1at baseline to -0.86 mmol l-1at the end of week 24, decreased by 1.02 mmol l-1(P<0.0001); and 25.3% of patients in the metformin group had LDL-C ≥3.37 mmol l-1, which is significantly <64.8% in the placebo group (P<0.001) at week 24. Compared with the placebo, metformin treatment also have a significant effect on reducing weight, body mass index, insulin, insulin resistance index, total cholesterol and triglyceride, and increasing high-density lipoprotein cholesterol. The treatment effects on weight and insulin resistance appeared at week 12 and further improved at week 24, but the effects on improving dyslipidemia only significantly occurred at the end of week 24. We found that metformin treatment was effective in improving antipsychotic-induced dyslipidemia and insulin resistance, and the effects improving antipsychotic-induced insulin resistance appeared earlier than the reducing dyslipidemia.
authors.affiliation: Mental Health Institute of the Second Xiangya Hospital, National Technology Institute of Psychiatry, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Changsha, Hunan, China.
authors.forename: R-R
authors.initials: RR
authors.lastname: Wu
authors.affiliation: Mental Health Institute of the Second Xiangya Hospital, National Technology Institute of Psychiatry, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Changsha, Hunan, China.|Division of Clinical Sciences, Lieber Institute for Brain Development, Baltimore, MD, USA.
authors.forename: F-Y
authors.initials: FY
authors.lastname: Zhang
authors.affiliation: Department Psychiatry at Case Western Reserve/University Hospital Case Medical Center, Cleveland, OH, USA.
authors.forename: K-M
authors.initials: KM
authors.lastname: Gao
authors.affiliation: Mental Health Institute of the Second Xiangya Hospital, National Technology Institute of Psychiatry, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Changsha, Hunan, China.
authors.forename: J-J
authors.initials: JJ
authors.lastname: Ou
authors.affiliation: Mental Health Institute of the Second Xiangya Hospital, National Technology Institute of Psychiatry, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Changsha, Hunan, China.
authors.forename: P
authors.initials: P
authors.lastname: Shao
authors.affiliation: Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
authors.forename: H
authors.initials: H
authors.lastname: Jin
authors.affiliation: Mental Health Institute of the Second Xiangya Hospital, National Technology Institute of Psychiatry, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Changsha, Hunan, China.
authors.forename: W-B
authors.initials: WB
authors.lastname: Guo
authors.affiliation: Department Psychiatry at Case Western Reserve/University Hospital Case Medical Center, Cleveland, OH, USA.
authors.forename: P K
authors.initials: PK
authors.lastname: Chan
authors.affiliation: Mental Health Institute of the Second Xiangya Hospital, National Technology Institute of Psychiatry, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Changsha, Hunan, China.
authors.forename: J-P
authors.initials: JP
authors.lastname: Zhao
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001786:Blood Glucose; D001835:Body Weight / Q000187:drug effects; D004311:Double-Blind Method; D050171:Dyslipidemias / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin; D007333:Insulin Resistance; D008077:Lipoproteins, LDL / Q000032:analysis / Q000097:blood; D008297:Male; D008687:Metformin / Q000494:pharmacology* / Q000627:therapeutic use*; D009765:Obesity / Q000188:drug therapy; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy; D015430:Weight Gain / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D008077:Lipoproteins, LDL; D008687:Metformin
references.citation: Handb Exp Pharmacol. 2012;(212):135-64
references.pmid: 23129331
references.citation: J Clin Invest. 2000 Aug;106(4):453-8
references.pmid: 10953019
references.citation: Diabetes Care. 2015 Oct;38(10):1858-67
references.pmid: 26251408
references.citation: Kidney Int. 2015 Mar;87(3):497-9
references.pmid: 25723632
references.citation: Clin Chim Acta. 2006 Jun;368(1-2):1-19
references.pmid: 16480697
references.citation: Am J Psychiatry. 2008 Mar;165(3):352-8
references.pmid: 18245179
references.citation: Curr Vasc Pharmacol. 2014;12(4):653-7
references.pmid: 23627975
references.citation: Diabetologia. 2013 Sep;56(9):1898-906
references.pmid: 23835523
references.citation: Nat Rev Endocrinol. 2011 Oct 18;8(2):114-26
references.pmid: 22009159
references.citation: Am J Manag Care. 2002 Jan;Suppl:3, 5
references.pmid: 11833454
references.citation: Expert Opin Drug Saf. 2015 Jan;14(1):73-96
references.pmid: 25400109
references.citation: N Engl J Med. 2015 Jun 18;372(25):2448-50
references.pmid: 26039520
references.citation: Diabetes Care. 1998 May;21(5):701-5
references.pmid: 9589227
references.citation: Am J Psychiatry. 2016 Jan;173(1):53-9
references.pmid: 26481172
references.citation: Am J Psychiatry. 2012 Aug;169(8):813-21
references.pmid: 22711171
references.citation: Cardiovasc Diabetol. 2013 Aug 19;12:118
references.pmid: 23958390
references.citation: Schizophr Res. 2009 Aug;113(1):19-26
references.pmid: 19515536
references.citation: Psychopharmacology (Berl). 2006 Jul;186(4):572-8
references.pmid: 16601995
references.citation: J Clin Invest. 2007 May;117(5):1422-31
references.pmid: 17476361
references.citation: N Engl J Med. 2005 Sep 22;353(12 ):1209-23
references.pmid: 16172203
references.citation: Am J Med. 2005 Apr;118 Suppl 2:15S-22S
references.pmid: 15903291
references.citation: Treat Endocrinol. 2003;2(4):231-45
references.pmid: 15966559
references.citation: Clin Cornerstone. 2006;8 Suppl 1:S21-7
references.pmid: 16903166
references.citation: Atherosclerosis. 2010 Jul;211(1):260-5
references.pmid: 20356594
references.citation: J Lipid Res. 2004 Mar;45(3):507-12
references.pmid: 14657199
references.citation: J Biol Chem. 2000 Mar 24;275(12):8416-25
references.pmid: 10722675
references.citation: Am J Psychiatry. 2012 Jul;169(7):725-34
references.pmid: 22706279
references.citation: Med J Malaysia. 2012 Feb;67(1):39-44
references.pmid: 22582547
references.citation: Endocr Pract. 2012 Mar-Apr;18 Suppl 1:1-78
references.pmid: 22522068
references.citation: Med J Aust. 2003 May 5;178 Suppl:S67-70
references.pmid: 12720526
references.citation: Schizophr Res. 2007 Jul;93(1-3):99-108
references.pmid: 17490862
references.citation: Diabetes Care. 1997 Jul;20(7):1087-92
references.pmid: 9203442
references.citation: Curr Cardiol Rep. 2012 Dec;14(6):709-20
references.pmid: 22965836
references.citation: Indian J Clin Biochem. 2012 Oct;27(4):363-9
references.pmid: 24082461
references.citation: Cell Metab. 2011 Nov 2;14(5):575-85
references.pmid: 22055501
references.citation: Endocr Pract. 2012 Mar-Apr;18(2):269-93
references.pmid: 22507559
references.citation: JAMA. 2008 Jan 9;299(2):185-93
references.pmid: 18182600
references.citation: Indian J Exp Biol. 2011 May;49(5):332-8
references.pmid: 21615056
references.citation: J Clin Psychiatry. 2008;69 Suppl 1:32-44
references.pmid: 18484806
references.citation: Schizophr Res Treatment. 2013;2013:502697
references.pmid: 24490071